SurvodutideExplore study findings
Why the two LIVERAGE studies use different liver outcomes
3 numbered sourcesSource years 2024, 2026
Peptides are short amino-acid chains connected by peptide bonds. A designed peptide can activate receptors involved in how the body uses and stores nutrients. Survodutide is an investigational peptide that acts on the glucagon and GLP-1 receptors. The LIVERAGE registry records describe two trials that ask different questions about liver disease at different stages of scarring. [1, 2, 3]
One trial enrolls adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced scarring without cirrhosis. Its first part lists outcomes based on the appearance of liver tissue. One asks whether MASH resolves without worsening scarring. Another asks whether scarring improves by at least one stage without MASH getting worse. The paired conditions keep the two features of liver disease in view. [1]
The other trial studies people who already have compensated cirrhosis due to MASH. In compensated cirrhosis the liver has extensive scarring but continues to perform its major functions without the specified complications that mark decompensation. The registry’s main outcome combines clinical events and disease progression measures over a longer period. Examples include a liver transplant, decompensation or progression to a level of pressure in the liver’s blood vessels that the protocol defines as clinically significant. [2]
Both records were updated in October 2026 and listed no posted results. The records describe who the investigators plan to study and which outcomes will be compared. They do not provide estimates of benefit or risk. By using different outcomes for different stages of disease, the two trials can address distinct questions about what happens to liver tissue and what happens to people over time. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Boehringer Ingelheim. A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis. ClinicalTrials.gov (publication 2024-10-09, record updated 2026-10-28). (opens in a new tab)
clinicaltrials.gov↩ Back to text
- 2.Boehringer Ingelheim. A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis. ClinicalTrials.gov (publication 2024-10-09, record updated 2026-10-28). (opens in a new tab)
clinicaltrials.gov↩ Back to text
